ARCHIVES

FDA Committee Okays Carboplatin For Second Line Ovarian Cancer

This article is from The Cancer Letter archive.

Vol. 15 No. 01 | January 6, 1989

Download PDF Visit The Full Archive

Related Articles

Aflibercept-Docetaxel Combination Misses Primary Survival Endpoint

March 25, 2011

Spending Bill Could Give 15% Raise To NIH; Gimmicks Complicate Picture, Veto Looms

November 5, 1999

NCI to Recompete contracts for Frederick

December 4, 1992

NIH Review Process A Disaster, Borek Says

October 19, 1979

HHS Task Force Says NCI Drug Program Effective, Otters Suggestions; DeVita Responds

March 26, 1982

Draft of National Action Plan On Breast Cancer Targets Health Care, Research, Policy

March 23, 1994